← All trials
NCT03696459
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 2, 2018
- Primary completion
- Sep 20, 2019
- Completion date
- Sep 20, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johnson and JohnsonLead sponsor
- Johnson and JohnsonStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.